FDA authorises restart of the COVID-19 AZD 1222 vaccine US phase III trial.- AstraZeneca
Read time: 1 mins
Last updated:26th Oct 2020
Published:24th Oct 2020
Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD 1222, have resumed across the world with regulators in the US, UK, Brazil, South Africa and Japan confirming that it was safe to do so. The FDA authorised the restart in the US, following the resumption of trials in other countries in recent weeks.
Condition: Coronavirus/COVID-19 Infection